Market News & Trends
REGENXBIO to Acquire Dimension Therapeutics
REGENXBIO Inc. and Dimension Therapeutics, Inc. recently announced they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction…
Intra-Cellular Therapies Announces Positive Regulatory Update
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently announced that the U.S. Food and…
SiO2 Medical Products & Sanaria Sign Agreement for Cryogenic Vials
SiO Medical Products, Inc., a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, and Sanaria Inc., a U.S.-based developer, manufacturer,…
Novartis Injection Could Prevent Heart Attacks, Slash Cancer Risk
By Ben Spencer, Medical Correspondent Thousands of lives could be saved thanks to a new heart drug hailed as the biggest breakthrough since…
Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line
Ajinomoto Althea, a leading service provider of biopharmaceutical contract development and manufacturing drug programs, announces the installation and launch of a new high-performance sterile…
Cardiovascular Disease - Innovation Within Dyslipidemia, Heart Failure & Thrombosis Set to Reduce High CVD Mortality Rate
With over 1,400 products in active development, the innovation pipeline for cardiovascular disease (CVD) is extensive, with four key CVD indications – hypertension,…
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study
Mateon Therapeutics, Inc. recently announced results from its second scheduled interim analysis of the ongoing Phase 2/3 FOCUS study evaluating CA4P in combination with bevacizumab…
Fate Therapeutics Announces Issuance of Patent Covering Use of Viral Transduction Enhancers
Fate Therapeutics, Inc. recently announced the US Patent and Trademark Office has issued US Patent No. 9,675,641 covering the use of prostaglandins as viral transduction…
Monsanto & ToolGen Announce Global Licensing Agreement
Monsanto Company and ToolGen, Inc. recently announced the companies have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop…
Portola Pharmaceuticals Announces BLA Resubmission Accepted for Review
Portola Pharmaceuticals Inc. recently announced the US FDA has found its resubmitted Biologics License Application (BLA) for AndexXa (andexanet alfa) to be acceptable for review,…
Fortress Biotech Forms New Subsidiary to Develop Novel AAV Gene Therapy Treatments
Fortress Biotech, Inc. recently announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc., to develop novel gene therapy approaches for complement-mediated diseases. The…
PolyPid Completes Enrollment in Phase Ib/II Study of D-PLEX
PolyPid Ltd. recently announced the completion of enrollment in its Phase Ib/II study of D-PLEX (Doxycycline/Polymer-Lipid Encapsulation Matrix), the company’s lead product candidate, for the…
Manufacturing Process Scale-Up for Phase III: Clear Sailing or Storms Ahead?
Some drug developers diligently design scalability into their formulations from day one and are fully prepared for larger-scale production during Phase III. Essentially, their only…
Galena Biopharma Enters Merger Agreement With SELLAS Life Sciences
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd recently announced they have entered into an all stock definitive merger agreement under which SELLAS will…
Humanigen Announces Completion of Bioavailability Study
Humanigen, Inc. recently announced it has completed enrollment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is a key…
SGS Expands & Increases Capacity 50%
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, IL. The expansion…
Avista Pharma Solutions Completes Expansion of Analytical Laboratories
Avista Pharma Solutions, Inc. recently announced that the expansion and upgrades to the Analytical Laboratories at its Durham, NC, facility are now complete. These enhancements…
Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity
Cambrex Corporation recently announced it is to invest $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, IA,…
Aclaris Therapeutics Acquires Confluence Life Sciences
Aclaris Therapeutics Acquires Confluence Life Sciences Aclaris Therapeutics, Inc. recently announced it has acquired Confluence Life Sciences, Inc., a privately held biotechnology company focused on…
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements in Decades on Cancer Treatments
Small nimble biotechs to introduce a “golden age” of next-generation therapies like CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors …
